According to a phase III study published in the "World Journal of Gastroenterology", 40 mg Fexuprazan once daily can be a promising alternative to 40 mg Esomeprazole once daily for erosive esophagitis-affected people in terms of safety and efficacy. Researchers aimed to contrast Fexuprazan to Esomeprazole and determine its safety and effectiveness in erosive esophagitis patients.

Adult subjects with erosive esophagitis were randomly segregated (1:1) to receive either 40 mg Fexuprazan or 40 mg Esomeprazole once a day for 8 weeks in this randomized controlled study. The percentage of patients who had healed erosive esophagitis as determined by endoscopy at week 8 was the major endpoint. The quality of life evaluation, symptom response, and healing rate of erosive esophagitis at week 4 were the secondary objectives ascertained. Serum gastrin levels and safety characteristics were contrasted between the groups.

Out of 263 participants who were randomly assigned, 218 finished the trial according to the protocol (40 mg Fexuprazan, n = 107; 40 mg Esomeprazole, n = 111). At week 8, Fexuprazan exhibited non-inferiority to Esomeprazole in terms of the rate of healing. In terms of symptom responses and quality of life evaluations, there were no between-group differences in the erosive esophagitis healing rate at week 4, as shown in Table 1:

There was no inter-group difference in drug-associated side effects as well as serum gastrin levels at weeks 4 and 8.